

# AssayMax™ HARS ELISA Kit

Assaypro LLC 3400 Harry S Truman Blvd St. Charles, MO 63301 T (636) 447-9175 F (636) 395-7419 www.assaypro.com

For any questions regarding troubleshooting or performing the assay, please contact our support team at support@assaypro.com.

Thank you for choosing Assaypro.

# **Assay Summary**

**Step 1**. Add 50  $\mu$ l of Standard or Sample per well. Incubate 2 hours.

**Step 2.** Wash, then add 50  $\mu$ l of Biotinylated Antibody per well. Incubate 2 hours.

Step 3. Wash, then add 50  $\mu l$  of SP Conjugate per well. Incubate 30 minutes.

**Step 4.** Wash, then add 50  $\mu$ l of Chromogen Substrate per well. Incubate 25 minutes.

**Step 5.** Add 50  $\mu$ l of Stop Solution per well. Read at 450 nm immediately.

# Symbol Key



Consult instructions for use.

# Assay Template

12								
11								
10								
6								
8								
7								
9								
ß								
4								
m								
2								
1								
	A	B	С	D	Е	ł	Ð	н

# AssayMax<sup>™</sup> Histidyl-tRNA Synthetase (HARS, Jo-1) ELISA Kit

Catalog No. EH4820-1 Sample insert for reference use only

## Introduction

Histidyl tRNA Synthetase (HARS, HisRS, Jo-1) is a member of the aminoacyl tRNA synthetase (ARS) family of enzymes. HARS consists of 509 amino acids with a molecular mass of 57 kDa and is located in the cytoplasm (1). It catalyzes the ATP-dependent ligation of histidine to the 3'-end of its cognate tRNA via the formation of an aminoacyl-adenylate intermediate and plays a role in axon guidance. The enzyme is a frequent target of autoantibodies in the human autoimmune disease myositis characterized by weakness and wasting of muscle (2). Autoimmunity to HARS is initiated and propagated in a myositis-interstitial lung disease overlap syndrome (3). HARS mutations are linked to recessive Usher syndrome type 3B disorder with progressive vision and hearing loss during early childhood (4), and inherited motor and sensory peripheral neuropathy Charcot-Marie-Tooth disease type 2W characterized by muscle weakness and sensory loss in the distal extremities (5). The retina is particularly sensitive to a global reduction in HARS expression. In response to HARS knock down, the neural progenitors exhibit cell cycle arrest and cell death (6).

## Principle of the Assay

The AssayMax<sup>™</sup> HARS ELISA (Enzyme-Linked Immunosorbent Assay) Kit is designed for detection of HARS in **plasma**, **serum**, **and cell lysate samples**. This kit has been validated using **bovine and human samples**. This assay employs a quantitative **sandwich enzyme immunoassay** technique that measures HARS in approximately 5 hours. A polyclonal antibody specific for HARS has been pre-coated onto a 96-well microplate with removable strips. HARS in standards and samples is sandwiched by the immobilized antibody and a biotinylated polyclonal antibody specific for HARS, which is recognized by a streptavidin-peroxidase (SP) conjugate. All unbound material is washed away and a peroxidase enzyme substrate is added. The color development is stopped and the intensity of the color is measured.

## **Caution and Warning**

- This product is for **Research Use Only** and is not intended for use in diagnostic procedures.
- Prepare all reagents (diluent buffer, wash buffer, standard, biotinylated antibody, and SP conjugate), as instructed, prior to running the assay.
- Prepare all samples prior to running the assay. The dilution factors for the samples are suggested in this insert. However, the user should determine the optimal dilution factor.
- Spin down the SP conjugate vial and the biotinylated antibody vial before opening and using contents.
- The Stop Solution is an acidic solution.
- The kit should not be used beyond the expiration date.

#### Reagents

- HARS Microplate: A 96-well polystyrene microplate (12 strips of 8 wells) coated with a polyclonal antibody against HARS.
- Sealing Tapes: Each kit contains 3 precut, pressure sensitive sealing tapes that can be cut to fit the format of the individual assay.
- HARS Standard: HARS in a buffered protein base (7.2 ng, lyophilized).
- **Biotinylated HARS Antibody (50x):** A 50-fold concentrated biotinylated polyclonal antibody against HARS (120 μl).
- **EIA Diluent Concentrate (10x):** A 10-fold concentrated buffered protein base (20 ml).
- Wash Buffer Concentrate (20x): A 20-fold concentrated buffered surfactant (30 ml, 2 bottles).
- SP Conjugate (100x): A 100-fold concentrate (80 µl).
- **Chromogen Substrate (1x):** A stabilized peroxidase chromogen substrate tetramethylbenzidine (7 ml).
- Stop Solution (1x): A 0.5 N hydrochloric acid solution to stop the chromogen substrate reaction (11 ml).

## **Storage Condition**

- Upon arrival, immediately store components of the kit at recommended temperatures up to the expiration date.
- Store Standard, SP Conjugate, and Biotinylated Antibody at -20°C.
- Store Microplate, Diluent Concentrate (10x), Wash Buffer, Stop Solution, and Chromogen Substrate at 2-8°C.
- Unused microplate wells may be returned to the foil pouch with the desiccant packs and resealed. May be stored for up to 30 days in a vacuum desiccator.

## **Other Supplies Required**

- Microplate reader capable of measuring absorbance at 450 nm
- Pipettes (1-20 μl, 20-200 μl, 200-1000 μl, and multiple channel)
- Deionized or distilled reagent grade water

#### Sample Collection, Preparation, and Storage

- **Plasma:** Collect plasma using one-tenth volume of 0.1 M sodium citrate as an anticoagulant. Centrifuge samples at 3000 x g for 10 minutes and collect plasma. The sample is suggested for use at 1x; however, user should determine optimal dilution factor depending on application needs. The undiluted samples can be stored at -20°C or below for up to 3 months. Avoid repeated freeze-thaw cycles (EDTA or Heparin can also be used as an anticoagulant).
- Serum: Samples should be collected into a serum separator tube. After clot formation, centrifuge samples at 3000 x g for 10 minutes and remove serum. An 8-fold sample dilution is suggested into EIA Diluent or within the range of 2x 20x; however, user should determine optimal dilution factor depending on application needs. The undiluted samples can be stored at -20°C or below for up to 3 months. Avoid repeated freeze-thaw cycles.
- Cell Lysate: Rinse cell with cold PBS and then scrape the cell into a tube with 5 ml of cold PBS and 0.5 M EDTA. Centrifuge suspension at 1500 rpm for 10 minutes at 4°C and aspirate supernatant. Resuspend pellet in ice-cold Lysis Buffer (PBS, 1% Triton X-100, protease inhibitor cocktail). For every 1 x 10<sup>6</sup> cells, add approximately 100 µl of ice-cold Lysis Buffer. Incubate on ice for 60 minutes. Centrifuge at 13000 rpm for 30 minutes at 4°C and collect supernatant. If necessary, dilute samples into EIA Diluent; user should determine optimal dilution factor depending on application needs. The undiluted samples can be stored at -80°C. Avoid repeated freeze-thaw cycles.

Applicable samples may also include biofluids, cell culture, and tissue homogenates. If necessary, user should determine optimal dilution factor depending on application needs.

Refer to Dilution Guidelines for further instruction.

	<b>Guidelines for Dilutions of 100-fold or Greater</b> (for reference only; please follow the insert for specific dilution suggested)					
	100x	10000x				
A)	4 μl sample : 396 μl buffer (100x)	A)	4 μl sample : 396 μl buffer (100x)			
	= 100-fold dilution	B)	4 μl of A : 396 μl buffer (100x)			
			= 10000-fold dilution			
	Assuming the needed volume is less than		Assuming the needed volume is less than			
	or equal to 400 μl.		or equal to 400 μl.			
	1000x		100000x			
A)	4 μl sample : 396 μl buffer (100x)	A)	4 μl sample : 396 μl buffer (100x)			
B)	24 μl of A : 216 μl buffer (10x)	B)	4 μl of A : 396 μl buffer (100x)			
	= 1000-fold dilution	C)	24 μl of B : 216 μl buffer (10x)			
			= 100000-fold dilution			
	Assuming the needed volume is less than		Assuming the needed volume is less than			
	or equal to 240 μl.		or equal to 240 μl.			

## **Reagent Preparation**

- Freshly dilute all reagents and bring all reagents to room temperature before use.
- **EIA Diluent Concentrate (10x):** Dilute the EIA Diluent Concentrate 10fold with reagent grade water to produce a 1x solution. When diluting the concentrate, make sure to rinse the bottle thoroughly to extract any precipitates left in the bottle. Mix the 1x solution gently until the crystals have completely dissolved. Store for up to 30 days at 2-8°C.
- HARS Standard: Reconstitute the HARS Standard (7.2 ng) with 1.2 ml of EIA Diluent to generate a 6 ng/ml standard stock solution. Allow the vial to sit for 10 minutes with gentle agitation prior to making dilutions. Prepare duplicate or triplicate standard points by serially diluting from the standard stock solution (6 ng/ml) 2-fold with equal volume of EIA Diluent to produce 3, 1.5, 0.75, 0.375, 0.188, and 0.094 ng/ml solutions. EIA Diluent serves as the zero standard (0 ng/ml). Aliquot remaining stock solution to limit repeated freeze-thaw cycles. This solution should be stored at -20°C and used within 5 days.

Standard Point	Dilution	[HARS] (ng/ml)
P1	1 part Standard (6 ng/ml)	6.0
P2	1 part P1 + 1 part EIA Diluent	3.0
P3	1 part P2 + 1 part EIA Diluent	1.5
P4	1 part P3 + 1 part EIA Diluent	0.75
P5	1 part P4 + 1 part EIA Diluent	0.375
P6	1 part P5 + 1 part EIA Diluent	0.188
P7	1 part P6 + 1 part EIA Diluent	0.094
P8	EIA Diluent	0.0

- Biotinylated HARS Antibody (50x): Spin down the antibody briefly and dilute the desired amount of the antibody 50-fold with EIA Diluent to produce a 1x solution. The undiluted antibody should be stored at -20°C.
- Wash Buffer Concentrate (20x): Dilute the Wash Buffer Concentrate 20fold with reagent grade water to produce a 1x solution. When diluting the concentrate, make sure to rinse the bottle thoroughly to extract any precipitates left in the bottle. Mix the 1x solution gently until the crystals have completely dissolved.
- SP Conjugate (100x): Spin down the SP Conjugate briefly and dilute the desired amount of the conjugate 100-fold with EIA Diluent to produce a 1x solution. The undiluted conjugate should be stored at -20°C.

#### **Assay Procedure**

- Prepare all reagents, standard solutions, and samples as instructed. Bring all reagents to room temperature before use. The assay is performed at room temperature (20-25°C).
- Remove excess microplate strips from the plate frame and return them immediately to the foil pouch with desiccants inside. Reseal the pouch securely to minimize exposure to water vapor and store in a vacuum desiccator.
- Add 50 μl of HARS Standard or sample to each well. Gently tap plate to thoroughly coat the wells. Break any bubbles that may have formed. Cover wells with a sealing tape and incubate for 2 hours. Start the timer after the last addition.
- Wash the microplate manually or automatically using a microplate washer. Invert the plate and decant the contents; hit 4-5 times on absorbent material to completely remove the liquid. If washing manually, wash five times with 200 µl of Wash Buffer per well. Invert the plate each time and decant the contents; hit 4-5 times on absorbent material to completely remove the liquid. If using a microplate washer, wash six times with 300 µl of Wash Buffer per well; invert the plate and hit 4-5 times on absorbent material to completely remove the liquid.

- Add 50 µl of Biotinylated HARS Antibody to each well. Gently tap plate to thoroughly coat the wells. Break any bubbles that may have formed. Cover wells with a sealing tape and incubate for 2 hours.
- Wash the microplate as described above.
- Add 50 μl of SP Conjugate to each well. Gently tap plate to thoroughly coat the wells. Break any bubbles that may have formed. Cover wells with a sealing tape and incubate for 30 minutes. Turn on the microplate reader and set up the program in advance.
- Wash the microplate as described above.
- Add 50 μl of Chromogen Substrate to each well. Gently tap plate to thoroughly coat the wells. Break any bubbles that may have formed. Incubate in ambient light for 25 minutes or until the optimal blue color density develops.
- Add 50 µl of Stop Solution to each well. The color will change from blue to yellow. Gently tap plate to ensure thorough mixing. Break any bubbles that may have formed.
- Read the absorbance on a microplate reader at a wavelength of 450 nm immediately. If wavelength correction is available, subtract readings at 570 nm from those at 450 nm to correct optical imperfections. Otherwise, read the plate at 450 nm only. Please note that some unstable black particles may be generated at high concentration points after stopping the reaction for about 10 minutes, which will reduce the readings.

## Data Analysis

- Calculate the mean value of the duplicate or triplicate readings for each standard and sample.
- To generate a standard curve, plot the graph using the standard concentrations on the x-axis and the corresponding mean 450 nm absorbance (OD) on the y-axis. The best fit line can be determined by regression analysis using log-log or four-parameter logistic curve fit.
- Determine the unknown sample concentration from the Standard Curve and multiply the value by the dilution factor.


## **Typical Data**

• The typical data is provided for reference only. Individual laboratory means may vary from the values listed. Variations between laboratories may be caused by technique differences.

Standard Point	ng/ml	OD	Average OD
P1	6.0	1.635	1.608
11	0:0	1.581	1.000
P2	3.0	1.295	1.316
۲Z	5.0	1.337	1.510
Р3	1.5	1.010	0.996
P3	1.5	0.982	0.996
D4	0.75	0.711	0.705
P4		0.699	0.705
DE	0.375	0.490	0.404
P5		0.478	0.484
P6	0.100	0.351	0.352
PO	0.188	0.353	0.352
Р7	0.094	0.284	0.279
۳/	0.094	0.274	0.279
00	0.0	0.186	0.188
P8 0.0		0.190	0.188

#### Standard Curve

• The curve is provided for illustration only. A standard curve should be generated each time the assay is performed.



HARS Standard Curve

## **Performance Characteristics**

• The minimum detectable dose of HARS as calculated by 2SD from the mean of a zero standard was established to be 64 pg/ml.

- Intra-assay precision was determined by testing three human serum samples twenty times in one assay.
- Inter-assay precision was determined by testing three human serum samples in twenty assays.

	Intra-Assay Precision			Inter-Assay Precision		
Sample	1	2	3	1	2	3
n	20	20	20	20	20	20
CV (%)	6.4%	4.9%	5.3%	10.5%	9.9%	8.7%
Average CV (%)	5.5%				9.7%	

#### Recovery

Standard Added Value	0.188 – 1.5 ng/ml	
Recovery %	86-116%	
Average Recovery %	104%	

#### Linearity

• Bovine and human serum samples were serially diluted to test for linearity.

Average Percentage of Expected Value (%)					
Sample Dilution Bovine Serum Human Serum					
4x	89%	102%			
8x	109%	109%			
16x	107%	89%			

#### **Cross-Reactivity**

Species	Cross-Reactivity (%)
Canine	50%
Bovine	70%
Human	100%
Monkey	70%
Mouse	50%
Rat	50%
Swine	50%
Rabbit	15%

# Troubleshooting

Issue	Causes	Course of Action
	Use of improper	<ul> <li>Check the expiration date listed before use.</li> </ul>
	components	<ul> <li>Do not interchange components from different lots.</li> </ul>
	Improper wash step	<ul> <li>Check that the correct wash buffer is being used.</li> <li>Check that all wells are empty after aspiration.</li> <li>Check that the microplate washer is dispensing properly.</li> <li>If washing by pipette, check for proper pipetting technique.</li> </ul>
cisior	Splashing of reagents while loading wells	Pipette properly in a controlled and careful manner.
Low Precision	Inconsistent volumes loaded into wells	<ul> <li>Pipette properly in a controlled and careful manner.</li> <li>Check pipette calibration.</li> <li>Check pipette for proper performance.</li> </ul>
	Insufficient mixing of reagent dilutions	<ul> <li>Thoroughly agitate the lyophilized components after reconstitution.</li> <li>Thoroughly mix dilutions.</li> </ul>
	Improperly sealed microplate	<ul> <li>Check the microplate pouch for proper sealing.</li> <li>Check that the microplate pouch has no punctures.</li> <li>Check that three desiccants are inside the microplate pouch prior to sealing.</li> </ul>
gnal	Microplate was left unattended between steps	• Each step of the procedure should be performed uninterrupted.
Sig	Omission of step	• Consult the provided procedure for complete list of steps.
Unexpectedly Low or High Signal Intensity	Steps performed in incorrect order	Consult the provided procedure for the correct order.
	Insufficient amount of reagents added to wells	<ul><li>Check pipette calibration.</li><li>Check pipette for proper performance.</li></ul>
Int Int	Wash step was skipped	<ul> <li>Consult the provided procedure for all wash steps.</li> </ul>
ed	Improper wash buffer	<ul> <li>Check that the correct wash buffer is being used.</li> </ul>
xpect	Improper reagent preparation	<ul> <li>Consult reagent preparation section for the correct dilutions of all reagents.</li> </ul>
Une	Insufficient or prolonged incubation periods	<ul> <li>Consult the provided procedure for correct incubation time.</li> </ul>
Deficient Standard Curve Fit	Non-optimal sample dilution	<ul> <li>Sandwich ELISA: If samples generate OD values higher than the highest standard point (P1), dilute samples further and repeat the assay.</li> <li>Competitive ELISA: If samples generate OD values lower than the highest standard point (P1), dilute samples further and repeat the assay.</li> <li>User should determine the optimal dilution factor for samples.</li> </ul>
	Contamination of	A new tip must be used for each addition of different
tSi	reagents	samples or reagents during the assay procedure.
icien	Contents of wells evaporate	<ul> <li>Verify that the sealing film is firmly in place before placing the assay in the incubator or at room temperature.</li> </ul>
Def	Improper pipetting	<ul> <li>Pipette properly in a controlled and careful manner.</li> <li>Check pipette calibration.</li> <li>Check pipette for proper performance.</li> </ul>

	Insufficient mixing of reagent dilutions	<ul> <li>Thoroughly agitate the lyophilized components after reconstitution.</li> <li>Thoroughly mix dilutions.</li> </ul>
--	---	--

#### References

- (1) O'Hanlon TP et al. (1995) Biochem Biophys Res Commun. 210(2):556-566.
- (2) Mathews MB and Bernsterin RM. (1983) Nature. 304(5922):177-179.
- (3) Levine SM et al. (2007) Arthritis Rheum. 56(8):2729-2739.
- (4) Puffenberger E et al. (2012) PLoS One. 7(1):e28936.
- (5) Brozkova DS et al. (2015) Brain. 138(Pt 8):2161-2172.
- (6) Waldron A et al. (2019) Front Cell Dev Biol. 7:67.

Version 1.0